796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database

Background

LGSOC is a rare disease. Few data of large size have been published.

Methods

We conducted a multicenter retrospective analysis of LGSC patients selected from the French Epidemiological Strategy and Medical Economics Ovarian Cancer database between 2000 and 2019. This database includes all ovarian cancer pts treated in 18 French Comprehensive Cancer Centers. The main objective was to describe the management of these patients. Secondary objectives were to analyse progression-free survival (PFS) and overall survival (OS) and prognostic factors in the stage III/IV population.

Results

Out of the 13032 pts, 230 (1.8%) with a confirmed diagnosis of stage III (n=171)/IV (n=59) LGSOC were identified. Median age at diagnosis was 55.5y (19.8-88.2). 128 (55.6%) pts had primary debulking surgery (PDS) and 35 (15.2%) neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS). 49 (21.3%) pts did not have debulking surgery and 18 (7.9%) patients had surgery after 6 courses of NACT. 223 pts (97.0%) received platinum-based chemotherapy (PBC) including bevacizumab (Bev) for 79 pts (34.3%). Endocrine therapy maintenance was given in 27 pts. After a median follow up of 73.6m [69.9-80.0], median OS was 93.4m (95%CI [71.2-176.9]) in the whole population. Median OS according to timing of surgery was 146.0m (95%CI [110.4-NR]) with PDS vs. 75.5m (95%CI [48.7-Not Reached]) with NACT-IDS vs. 61.8m (95%CI [42.4-NR]) with 6 courses of NACT and closing surgery. Patients not candidate for surgery received PBC (n=49) +/-Bev (14/49) +/- maintenance endocrine therapy (13/49). With a median follow-up of 64.6m (38.6-93.6), median PFS and OS were 15.9m (95%CI [13.4-20.6]) and 38.0 m (95%CI [33.0-65.0]) respectively. OS multivariable analyses are shown in the table.

Table: 796P

Conclusions

In this large size population of advanced LGSOC, FIGO IV stage, absence of PDS and age are associated with poorer OS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

P. Pautier: Financial Interests, Personal, Advisory Board, 2015 , 2022 : PharmaMar; Financial Interests, Institutional, Advisory Board, 2020 : Roche, Clovis; Financial Interests, Institutional, Advisory Board, 2021: AstraZeneca; Financial Interests, Personal, Advisory Board, 2019-2020: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK; Financial Interests, Personal, Advisory Board, 2018-2019: Roche; Financial Interests, Institutional, Advisory Board, 2022 : MSD; Financial Interests, Personal and Institutional, Research Grant: PharmaMar; Financial Interests, Research Grant: ONXEO. F. Joly Lobbedez: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, MSD, Janssen, Ipsen, BMS, Bayer, Eisai; Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Astellas; Financial Interests, Institutional, Coordinating PI: GSK, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Other, travel: MSD, GSK. T. De La Motte Rouge: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, GSK, Clovis Oncology, Roche, Mylan, Tesaro, Gilead, Sanofi; Financial Interests, Institutional, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Institutional, Research Grant: Novartis, Pfizer, MSD, Seagen; Financial Interests, Institutional, Local PI: Roche, AstraZeneca, GSK, MSD, Pfizer, Netris Pharma; Non-Financial Interests, Advisory Role: French National Cancer Institute, Unicancer; Non-Financial Interests, Principal Investigator: Arcagy; Non-Financial Interests, Other, Co-Principal Investigator: Unicancer. R. Sabatier: Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Invited Speaker: EISAI, Clovis Oncology; Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Other, Travel fees: MSD, Novartis; Non-Financial Interests, Other, Congress fees: GSK. P. Colombo: Financial Interests, Personal, Invited Speaker: GSK, MSD. C. Pomel: Financial Interests, Personal, Advisory Board: Roche, Roche, GSK, PharmaMar, MSD; Financial Interests, Personal, Invited Speaker: Roche, GSK, PharmaMar. L. Bosquet: Financial Interests, Institutional, Full or part-time Employment, In charge of scientific projects at Unicancer, Health Data and Partnership Department: Unicancer. L. Gladieff: Financial Interests, Personal, Other, Congress funding: Viatris, Roche; Financial Interests, Institutional, Invited Speaker: MSD, Clovis, GSK, Eisai; Financial Interests, Institutional, Advisory Board: Clovis, GSK; Financial Interests, Personal, Invited Speaker: AstraZeneca. J. Frenel: Financial Interests, Personal, Advisory Board: Pfizer, Novocure, Pierre Fabre, Eisai, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: GSK, Amgen; Financial Interests, Institutional, Advisory Board: Exactscience, Lilly, Daiichi Sankyo, AstraZeneca, Clovis Oncology; Financial Interests, Institutional, Invited Speaker: Novartis, MSD; Financial Interests, Invited Speaker: AstraZeneca, Seagen, MSD, Daiichi Sankyo; Non-Financial Interests, Principal Investigator: Novartis, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, MSD. All other authors have declared no conflicts of interest.